NovaBay Pharmaceuticals, Inc. (NBY)
NYSEAMERICAN: NBY · Real-Time Price · USD
1.070
-0.040 (-3.60%)
Nov 6, 2025, 4:00 PM EST - Market closed
NovaBay Pharmaceuticals Revenue
NovaBay Pharmaceuticals had revenue of $9.78M in the twelve months ending June 30, 2025, up 113.47% year-over-year. In the year 2024, NovaBay Pharmaceuticals had annual revenue of $9.78M, down -6.45%.
Revenue (ttm)
$9.78M
Revenue Growth
+113.47%
P/S Ratio
0.62
Revenue / Employee
$698,643
Employees
14
Market Cap
6.43M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.78M | -674.00K | -6.45% |
| Dec 31, 2023 | 10.46M | -3.95M | -27.42% |
| Dec 31, 2022 | 14.40M | 4.20M | 41.16% |
| Dec 31, 2021 | 10.20M | 270.00K | 2.72% |
| Dec 31, 2020 | 9.93M | 3.34M | 50.54% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
NBY News
- 17 days ago - NovaBay Pharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing Standards - GlobeNewsWire
- 7 weeks ago - NovaBay Pharmaceuticals Issues a Reminder of Important Information Regarding the Pending Special Dividend and Upcoming 2025 Annual Meeting - GlobeNewsWire
- 2 months ago - NovaBay Pharmaceuticals Announces One-Time Special Cash Dividend of $0.80 Per Share - GlobeNewsWire
- 2 months ago - NovaBay Pharmaceuticals Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar - GlobeNewsWire
- 8 months ago - NovaBay Pharmaceuticals to Hold Special Meeting of Stockholders - Business Wire
- 10 months ago - NovaBay Pharmaceuticals Completes the Sale of its Eyecare Business to PRN and Further Adjourns its Special Meeting of Stockholders on Dissolution Proposal - Business Wire
- 11 months ago - NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders - Business Wire
- 11 months ago - NovaBay CEO Letter to Stockholders Urges a FOR Vote at Upcoming Reconvened Special Meeting - Business Wire